HCID 68866923, compound → HCID 54697528, compound
Reaction equation
C([O:8][C:9]1[C:17]2[C:16](=[O:18])[N:15]([CH2:19][C:20]3[CH:25]=[CH:24][C:23]([F:26])=[CH:22][CH:21]=3)[N:14]=[C:13]([O:27][CH3:28])[C:12]=2[N:11]2[CH2:29][CH2:30][N:31]([CH3:34])[C:32](=[O:33])[C:10]=12)C1C=CC=CC=1>[OH-].[OH-].[Pd+2].CO.C(#N)C>[F:26][C:23]1[CH:24]=[CH:25][C:20]([CH2:19][N:15]2[C:16](=[O:18])[C:17]3[C:9]([OH:8])=[C:10]4[C:32](=[O:33])[N:31]([CH3:34])[CH2:30][CH2:29][N:11]4[C:12]=3[C:13]([O:27][CH3:28])=[N:14]2)=[CH:21][CH:22]=1Participants
5
Reactant 1
Product 1
Reagents, catalysts & solvents 3
Procedure
A mixture of 10-(benzyloxy)-2-(4-fluorobenzyl)-4-methoxy-8-methyl-7,8-dihydropyrazino[1′,2′:1,5]-pyrrolo[2,3-d]pyridazine-1,9(2H,6H)-dione (23 mg, 0.05 mmol) and Pearlman's catalyst [23 mg, 20% Pd(OH)2 on carbon] in methanol (20 mL) was stirred under an atmosphere of hydrogen gas (1 atm) at room temperature for 25 minutes. The reaction mixture was diluted with acetonitrile and filtered. The filtrate was concentrated under vacuum, and the residue was subjected to purification on reverse phase HPLC. Collection and lyophilization of appropriate fractions provided the titled compound.
Workup
- filtrationfiltered
- concentrationThe filtrate was concentrated under vacuum
- customthe residue was subjected to purification on reverse phase HPLC
- customCollection and lyophilization of appropriate fractions
Sources & evidence
- ORD record
- ord-4dc9e447f13c4f94901ce7e75105c3c9
- Source dataset
- uspto-grants-2009_05
- Patent number
- US07538112B2
Reaction notes
Loading…